FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4318538870> ?p ?o ?g. }

• W4318538870 endingPage "512" @default.
• W4318538870 startingPage "501" @default.
• W4318538870 abstract "Roisin McGuigan, Editor,&#160;Immuno-Oncology Insights, speaks to Pravin TP Kaumaya, Professor and Director of Vaccine Research at The Ohio State UniversityPravin Kaumaya is Professor of Medicine in the Department of Ob/Gyn at the OSU Wexner Medical Center and the James Comprehensive Cancer Center. Dr Kaumaya is internationally recognized as an expert in the fields of vaccine research with emphasis on peptide vaccines for cancer. His work over three decades in developing B cell epitope-based cancer vaccines is a paradigm shift in the immune-oncology landscape. Dr Kaumaya is an elected fellow of the American Association for the Advancement of Science (AAAS), and he was elected as the treasurer of the American Peptide Society since 2009. He has lectured worldwide and has published over 130 peer-reviewed articles in major scientific journals. He conducts research in the areas of immune-oncology, tumor immunology, peptide design and immune mechanisms supported largely by NIH, Pelotonia and more recently by Imugene, Ltd. He is an inventor on several issued and pending patents for peptide cancer vaccines and immune-therapeutic technologies. Vaccines developed for HER-1, HER-3, IGF-1R and VEGF at the university has been licensed to IMUGENE Ltd. Dr Kaumaya has conducted two first man/woman NCI funded and FDA approved Phase 1 Trial in Cancer Patients (Stage four) with solid tumors in several indications (Breast, Ovarian, GIST) at the OSU James Cancer Hospital has recently been completed successfully demonstrating the safety and efficacy of the vaccine. Dr Kaumaya’s laboratory has recently developed a PD-1-Vaxx (programmed cell death) B cell peptide cancer vaccine that induces the body to produce polyclonal antibodies that block PD-1 signaling and produce an anticancer effect similar to the marketed immunotherapy drugs Keytruda&#174; and Opdivo&#174;." @default.
• W4318538870 created "2023-01-31" @default.
• W4318538870 creator A5017826930 @default.
• W4318538870 date "2022-11-21" @default.
• W4318538870 modified "2023-09-25" @default.
• W4318538870 title "A career in cancer vaccines: exploring the promise of B cell epitopes" @default.
• W4318538870 doi "https://doi.org/10.18609/ioi.2022.051" @default.
• W4318538870 hasPublicationYear "2022" @default.
• W4318538870 type Work @default.
• W4318538870 citedByCount "0" @default.
• W4318538870 crossrefType "journal-article" @default.
• W4318538870 hasAuthorship W4318538870A5017826930 @default.
• W4318538870 hasConcept C121608353 @default.
• W4318538870 hasConcept C126322002 @default.
• W4318538870 hasConcept C143998085 @default.
• W4318538870 hasConcept C159654299 @default.
• W4318538870 hasConcept C195616568 @default.
• W4318538870 hasConcept C203014093 @default.
• W4318538870 hasConcept C2776789287 @default.
• W4318538870 hasConcept C2777701055 @default.
• W4318538870 hasConcept C2778378633 @default.
• W4318538870 hasConcept C512399662 @default.
• W4318538870 hasConcept C71924100 @default.
• W4318538870 hasConceptScore W4318538870C121608353 @default.
• W4318538870 hasConceptScore W4318538870C126322002 @default.
• W4318538870 hasConceptScore W4318538870C143998085 @default.
• W4318538870 hasConceptScore W4318538870C159654299 @default.
• W4318538870 hasConceptScore W4318538870C195616568 @default.
• W4318538870 hasConceptScore W4318538870C203014093 @default.
• W4318538870 hasConceptScore W4318538870C2776789287 @default.
• W4318538870 hasConceptScore W4318538870C2777701055 @default.
• W4318538870 hasConceptScore W4318538870C2778378633 @default.
• W4318538870 hasConceptScore W4318538870C512399662 @default.
• W4318538870 hasConceptScore W4318538870C71924100 @default.
• W4318538870 hasIssue "03" @default.
• W4318538870 hasLocation W43185388701 @default.
• W4318538870 hasOpenAccess W4318538870 @default.
• W4318538870 hasPrimaryLocation W43185388701 @default.
• W4318538870 hasRelatedWork W2091020218 @default.
• W4318538870 hasRelatedWork W2102594276 @default.
• W4318538870 hasRelatedWork W2365364931 @default.
• W4318538870 hasRelatedWork W2418638721 @default.
• W4318538870 hasRelatedWork W2766518664 @default.
• W4318538870 hasRelatedWork W2794003560 @default.
• W4318538870 hasRelatedWork W2897496508 @default.
• W4318538870 hasRelatedWork W2950054659 @default.
• W4318538870 hasRelatedWork W3170310109 @default.
• W4318538870 hasRelatedWork W4237393139 @default.
• W4318538870 hasVolume "10" @default.
• W4318538870 isParatext "false" @default.
• W4318538870 isRetracted "false" @default.
• W4318538870 workType "article" @default.